TR201815173T4 - Peptit bileşimleri. - Google Patents

Peptit bileşimleri. Download PDF

Info

Publication number
TR201815173T4
TR201815173T4 TR2018/15173T TR201815173T TR201815173T4 TR 201815173 T4 TR201815173 T4 TR 201815173T4 TR 2018/15173 T TR2018/15173 T TR 2018/15173T TR 201815173 T TR201815173 T TR 201815173T TR 201815173 T4 TR201815173 T4 TR 201815173T4
Authority
TR
Turkey
Prior art keywords
arg
cys
trp
cyclo
phe
Prior art date
Application number
TR2018/15173T
Other languages
English (en)
Turkish (tr)
Inventor
Sharma Shubh
H T Van Der Ploeg Leonardus
Henderson Bart
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of TR201815173T4 publication Critical patent/TR201815173T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TR2018/15173T 2013-03-15 2014-03-14 Peptit bileşimleri. TR201815173T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
TR201815173T4 true TR201815173T4 (tr) 2018-11-21

Family

ID=50588892

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/15173T TR201815173T4 (tr) 2013-03-15 2014-03-14 Peptit bileşimleri.

Country Status (10)

Country Link
US (4) US10196425B2 (enExample)
EP (2) EP3450449A3 (enExample)
JP (4) JP6622690B2 (enExample)
CN (3) CN118271400A (enExample)
AU (5) AU2014227712B2 (enExample)
CA (1) CA2906694A1 (enExample)
ES (1) ES2693761T3 (enExample)
RU (2) RU2725150C2 (enExample)
TR (1) TR201815173T4 (enExample)
WO (1) WO2014144260A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539551T3 (pl) 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
AU2014227712B2 (en) 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
FI3356386T3 (fi) * 2015-09-30 2024-05-16 Rhythm Pharmaceuticals Inc Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
US11591367B2 (en) * 2016-10-04 2023-02-28 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
WO2018167194A1 (en) * 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
TW202228760A (zh) * 2020-09-24 2022-08-01 美商律森製藥股份有限公司 治療黑素皮質素-4受體路徑相關病症之方法
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用
CN120192363A (zh) * 2023-12-22 2025-06-24 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851002T2 (de) * 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
EP1315750B1 (en) * 2000-08-30 2007-02-14 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
JP2006527772A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
EP2236151B1 (en) * 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
RU2450017C2 (ru) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
WO2008156677A2 (en) 2007-06-15 2008-12-24 Ipsen Pharma S.A.S. Cyclic peptide melanocortin receptor ligands
CN103316345B (zh) 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
AU2010279719A1 (en) * 2009-08-05 2012-03-01 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
RU2012125033A (ru) 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
EP2970389B1 (en) * 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
AU2014227712B2 (en) 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions

Also Published As

Publication number Publication date
EP3450449A3 (en) 2019-06-12
AU2024200528A1 (en) 2024-02-15
HK1220697A1 (en) 2017-05-12
US20210040155A1 (en) 2021-02-11
AU2014227712A1 (en) 2015-10-01
JP2016516719A (ja) 2016-06-09
EP2970388A1 (en) 2016-01-20
RU2020120797A (ru) 2020-07-02
JP2025102830A (ja) 2025-07-08
CN105492456B (zh) 2024-11-01
US20160017001A1 (en) 2016-01-21
US20250188124A1 (en) 2025-06-12
US20190092815A1 (en) 2019-03-28
AU2021269411A1 (en) 2021-12-16
EP3450449A2 (en) 2019-03-06
US10858399B2 (en) 2020-12-08
CN105492456A (zh) 2016-04-13
AU2018256493A1 (en) 2018-11-22
JP2019172693A (ja) 2019-10-10
US10196425B2 (en) 2019-02-05
US12077612B2 (en) 2024-09-03
JP6622690B2 (ja) 2019-12-18
ES2693761T3 (es) 2018-12-13
AU2014227712B2 (en) 2018-08-02
CA2906694A1 (en) 2014-09-18
JP7654587B2 (ja) 2025-04-01
AU2020203353A1 (en) 2020-06-11
RU2725150C2 (ru) 2020-06-30
CN118240012A (zh) 2024-06-25
CN118271400A (zh) 2024-07-02
EP2970388B1 (en) 2018-07-25
WO2014144260A1 (en) 2014-09-18
JP7046871B2 (ja) 2022-04-04
JP2022084844A (ja) 2022-06-07
RU2015145593A (ru) 2017-04-24

Similar Documents

Publication Publication Date Title
TR201815173T4 (tr) Peptit bileşimleri.
Riesberg et al. Beyond muscles: The untapped potential of creatine
JP2009500427A5 (enExample)
CN103450112B (zh) 一种n-桥连接的含氮五元杂环化合物及其制备与用途
US9957226B2 (en) Antimicrobial compounds
AU2015326936B2 (en) Treatments for autoimmune disease
SG11201804363UA (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
NZ703851A (en) Compounds that are s1p modulating agents and/or atx modulating agents
JP2012041365A5 (enExample)
SG11201806542PA (en) Anti-mica antibodies
HUE031712T2 (en) Retinoids and retinoid-like compounds with positively charged water-soluble prodrugs having very high skin penetration rates
RU2019121667A (ru) Аминопиразолы в качестве селективных ингибиторов янус-киназы
JP6289659B2 (ja) 五環トリテルペン構造修飾化合物とその調製方法及び応用
SG11201907207UA (en) Pharmaceutical combinations comprising an anti-ly75 antibody
JP2017523230A (ja) 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
TW201034674A (en) Uses of NK receptor antagonists
SG11201804169QA (en) Rice grain with thickened aleurone
US10172822B2 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile
US10307383B2 (en) Cosmetic composition for preventing or ameliorating hypersensitive skin comprising cedrol or derivatives thereof, or pharmaceutically acceptable salts thereof
US9440916B2 (en) 3, 4-bis-benzylsulfonylbutyronitrile and its pharmaceutical use
US9610296B2 (en) Inducing lactation in nursing females
Kireev et al. Prospects of using antioxidant drugs for the treatment and prevention diseases of farm animals
US10273203B2 (en) Deuterated 3-methanesulfonylpropionitrile
CN107684552B (zh) 一种依托芬那酯贴剂
CN103819471A (zh) 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用